Ella Therapeutics

Ella Therapeutics is developing a microbiome-derived therapy to overcome resistance to immune checkpoint inhibitors for different indications. Our research program uses a unique Reverse Clinical Development method to isolate and characterize the agents within the microbiota that enhance sensitivity to immunotherapy, through advanced computational biology models to predict the relevant composition. Using the reverse clinical development approach allows us to identify unique causative data, which gives us huge advantages in reaching the targeted solution and shortening time to market.We employ a bedsidetobenchtop strategy by treating cancer patients who are refractory to standard immunotherapy with fecal microbiota transplantation (FMT) to alter their microbiome, reprogram their immune system and ultimately allow them to respond to standard immunotherapy. This creates causative, clinically proven, datasets. Through rigorous science, incorporating metagenomics, transcriptomics, proteomics, and metabolomics, we apply reverse engineering approach on these datasets to uncover and isolate the causative agents that enhance the sensitivity to immunotherapy. This will facilitate the path towards manufacturable treatments.